| 1 |
Liu L, Simon B, Shi J, et al. Impact of diabetes mellitus on risk of cardiovascular disease and all-cause mortality: evidence on health outcomes and anti-diabetic treatment in United States adults [J]. World J Diabetes, 2016, 7(18): 449-461.
|
| 2 |
Hippisley-Cox J, Coupland C. Diabetes treatments and risk of heart failure, cardiovascular disease, and all cause mortality: cohort study in primary care [J]. BMJ, 2016, 354: i3477.
|
| 3 |
Lang RM, Badano LP, Mor-Avi V, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging [J]. J Am Soc Echocardiogr, 2015, 28(1): 1-39.
|
| 4 |
Mcmurray JJ, Gerstein HC, Holman RR, et al. Heart failure: a cardiovascular outcome in diabetes that can no longer be ignored [J]. Lancet Diabetes Endocrinol, 2014, 2(10): 843-851.
|
| 5 |
Loncarevic B, Trifunovic D, Soldatovic I, et al. Silent diabetic cardiomyopathy in everyday practice: a clinical and echocardiographic study [J]. BMC Cardiovasc Disord, 2016, 16(1): 242.
|
| 6 |
Jia G, Hill MA, Sowers JR. Diabetic cardiomyopathy: an update of mechanisms contributing to this clinical entity [J]. Circ Res, 2018, 122(4): 624-638.
|
| 7 |
Ernande L, Bergerot C, Rietzschel ER, et al. Diastolic dysfunction in patients with type 2 diabetes mellitus: is it really the first marker of diabetic cardiomyopathy [J]. J Am Soc Echocardiogr, 2011, 24(11): 1268-1275.
|
| 8 |
Holland DJ, Marwick TH, Haluska BA, et al. Subclinical LV dysfunction and 10-year outcomes in type 2 diabetes mellitus [J]. Heart, 2015, 101(13): 1061-1066.
|
| 9 |
Hoogslag GE, Abou R, Joyce E, et al. Comparison of changes in global longitudinal peak systolic strain after ST-segment elevation myocardial infarction in patients with versus without diabetes mellitus [J]. Am J Cardiol, 2015, 116(9): 1334-1339.
|
| 10 |
Jensen MT, Sogaard P, Gustafsson I, et al. Echocardiography improves prediction of major adverse cardiovascular events in a population with type 1 diabetes and without known heart disease: the Thousand & 1 Study [J]. Diabetologia, 2019, 62(12): 2354-2364.
|
| 11 |
Raskin P. Sodium-glucose cotransporter inhibition: therapeutic potential for the treatment of type 2 diabetes mellitus [J]. Diabetes Metab Res Rev, 2013, 29(5): 347-356.
|
| 12 |
Wright EM, Loo DD, Hirayama BA. Biology of human sodium glucose transporters [J]. Physiol Rev, 2011, 91(2): 733-794.
|
| 13 |
Ferrannini E, Solini A. SGLT2 inhibition in diabetes mellitus: rationale and clinical prospects [J]. Nat Rev Endocrinol, 2012, 8(8): 495-502.
|
| 14 |
Quagliariello V, De Laurentiis M, Rea D, et al. The SGLT-2 inhibitor empagliflozin improves myocardial strain, reduces cardiac fibrosis and pro-inflammatory cytokines in non-diabetic mice treated with doxorubicin [J]. Cardiovasc Diabetol, 2021, 20(1): 150.
|
| 15 |
Hammoudi N, Jeong D, Singh R, et al. Empagliflozin improves left ventricular diastolic dysfunction in a genetic model of type 2 diabetes [J]. Cardiovasc Drugs Ther, 2017, 31(3): 233-246.
|
| 16 |
Santos-Gallego CG, Requena-Ibanez JA, San Antonio R, et al. Empagliflozin ameliorates adverse left ventricular remodeling in nondiabetic heart failure by enhancing myocardial energetics [J]. J Am Coll Cardiol, 2019, 73(15): 1931-1944.
|
| 17 |
Park JJ, Park JB, Park JH, et al. Global longitudinal strain to predict mortality in patients with acute heart failure [J]. J Am Coll Cardiol, 2018, 71(18): 1947-1957.
|
| 18 |
Omar M, Jensen J, Ali M, et al. Associations of empagliflozin with left ventricular volumes, mass, and function in patients with heart failure and reduced ejection fraction: a substudy of the empire HF randomized clinical trial [J]. JAMA Cardiol, 2021, 6(7): 836-840.
|
| 19 |
Lee MMY, Brooksbank KJM, Wetherall K, et al. Effect of empagliflozin on left ventricular volumes in patients with type 2 diabetes, or prediabetes, and heart failure with reduced ejection fraction [J]. Circulation, 2021, 143(6): 516-525.
|
| 20 |
李晨光. 恩格列净对糖尿病心肌氧化应激和纤维化的机制研究 [D]. 天津: 天津医科大学, 2019.
|
| 21 |
Santos-Gallego CG, Vargas-Delgado AP, Requena-Ibanez JA, et al. Randomized trial of empagliflozin in nondiabetic patients with heart failure and reduced ejection fraction [J]. J Am Coll Cardiol, 2021, 77(3): 243-255.
|
| 22 |
Connelly KA, Zhang Y, Visram A, et al. Empagliflozin improves diastolic function in a rodent model of heart failure with preserved ejection fraction [J]. JACC Basic Transl Sci, 2019, 4(1): 27-37.
|
| 23 |
Santos-Gallego CG, Requena-Ibanez JA, San Antonio R, et al. Empagliflozin ameliorates diastolic dysfunction and left ventricular fibrosis/stiffness in nondiabetic heart failure: a multimodality study [J]. JACC Cardiovasc Imaging, 2021, 14(2): 393-407.
|
| 24 |
Gulsin GS, Swarbrick DJ, Hunt WH, et al. Relation of aortic stiffness to left ventricular remodeling in younger adults with type 2 diabetes [J]. Diabetes, 2018, 67(7): 1395-1400.
|
| 25 |
Matsutani D, Sakamoto M, Kayama Y, et al. Effect of canagliflozin on left ventricular diastolic function in patients with type 2 diabetes [J]. Cardiovasc Diabetol, 2018, 17(1): 73.
|
| 26 |
Sezai A, Sekino H, Unosawa S, et al. Canagliflozin for Japanese patients with chronic heart failure and type II diabetes [J]. Cardiovasc Diabetol, 2019, 18(1): 76.
|
| 27 |
Soga F, Tanaka H, Tatsumi K, et al. Impact of dapagliflozin on left ventricular diastolic function of patients with type 2 diabetic mellitus with chronic heart failure [J]. Cardiovasc Diabetol, 2018, 17(1): 132.
|
| 28 |
Devereux RB, Roman MJ, Paranicas M, et al. Impact of diabetes on cardiac structure and function: the strong heart study [J]. Circulation, 2000, 101(19): 2271-2276.
|
| 29 |
Packer M, Anker SD, Butler J, et al. Cardiovascular and renal outcomes with empagliflozin in heart failure [J]. N Engl J Med, 2020, 383(15): 1413-1424.
|
| 30 |
Anker SD, Butler J, Filippatos G, et al. Empagliflozin in heart failure with a preserved ejection fraction [J]. N Engl J Med, 2021, 385(16): 1451-1461.
|
| 31 |
Packer M, Butler J, Zannad F, et al. Effect of empagliflozin on worsening heart failure events in patients with heart failure and preserved ejection fraction: EMPEROR-Preserved trial [J]. Circulation, 2021, 144(16): 1284-1294.
|